A company developing a novel line of hybrid drugs that integrate digital interventions to target neuro-immune processes and enhance drug effectiveness.
investor of
Metrics
marketPRIVATE
msh_idCOM:REMEPY
websitehttps://www.remepy.com
source_ref16050f42-7103-4199-a0b4-a85f4a0e97c1
products_or_servicesHybrid drugs combining software with drugs to create new SaMD - Drug combinations, targeting brain connectivity and immune biomarkers